Iron Maltobionic Acid Complexes for Parenteral Anemia Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current iron deficiency treatments, particularly for anemia, face challenges with oral administration due to low absorption and side effects, and parenteral methods like intravenous administration are limited by the need for hospital use and potential side effects, with no authorized subcutaneous options available.
Innovation Solution
Development of low molecular weight complexes between iron and maltobionic acid, with a molecular weight between 10,000 and 30,000 Da, polydispersity of 1.0-1.8, and an iron content of 25-40% by weight, allowing for intramuscular and subcutaneous administration without serious adverse reactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If oral administration of iron salts is used, then ease of operation is improved, but absorption efficiency deteriorates and harmful factors increase
Solution Approach 1:
The patent changes the molecular weight parameter of iron complexes from high (traditional) to low (10,000-30,000 Da), and modifies the chemical structure by using maltobionic acid instead of conventional carriers. This enables the complex to be small enough for good absorption but stable enough for parenteral administration, resolving the contradiction between absorption efficiency and administration route
2Ease of operation
If oral administration of iron salts is used, then ease of operation is improved, but harmful factors increase due to side effects
Solution Approach 1:
The patent modifies the molecular weight and chemical structure parameters to create low molecular weight iron-maltobionic acid complexes (10,000-30,000 Da) that can be administered parenterally. This eliminates gastrointestinal side effects while maintaining ease of administration through simple injection or infusion
Solution Approach 2:
The patent uses maltobionic acid as an intermediary carrier molecule that binds iron in a stable complex. This intermediary prevents direct contact between free iron salts and biological tissues, eliminating the harmful side effects associated with traditional iron administration while facilitating safe delivery
3Reliability
If intravenous administration is used, then absorption certainty is improved, but device complexity and ease of operation worsen due to hospital requirement
Solution Approach 1:
The patent changes the molecular weight parameter to low (10,000-30,000 Da), which allows the iron complex to be administered through simpler routes (intramuscular or subcutaneous injection) rather than requiring intravenous infusion equipment and hospital settings. This maintains absorption certainty while dramatically improving administration convenience
4Stability of the object's composition
If high molecular weight iron complexes are used, then stability is improved, but bioavailability deteriorates
Solution Approach 1:
The patent optimizes the molecular weight parameter to a specific low range (10,000-30,000 Da) that provides the optimal balance between stability and bioavailability. This is achieved by controlling the degree of polymerization and using maltobionic acid as the carrier, which maintains complex integrity while allowing sufficient iron release for absorption
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These complexes provide stable, bioavailable, and non-toxic iron delivery at physiological pH, enabling easy administration in therapeutic dosages, including subcutaneously, reducing the risk of side effects and allowing for home use.
Implementation Method 1
new low molecular weight complexes between iron and maltobionic acid that can be administered parenterally
Data Source
AI summary
New low molecular weight complexes between iron and maltobionic acid that can be administered parenterally, preferably intramuscularly or subcutaneously, in the treatment of anemic states, caused by iron deficiencies, and new pharmaceutical compositions adapted for this use. In particular, the invention provides a new complex between preferably trivalent iron and maltobionic acid that is characterized by a molecular weight Mw between 10,000 and 30,000 Da, by a polydispersity of 1.0-1.8 and by an iron content between 25% and 40% by weight.